On October 27, the 11th round of China’s National Centralized Drug Procurement Program officially opened, marking another important step in China’s ongoing healthcare reform aimed at improving drug accessibility, enhancing supply efficiency, and reducing public medical expenditure. As one of the most influential pharmaceutical procurement mechanisms in China, the national centralized procurement program continues to reshape the domestic pharmaceutical market by prioritizing product quality, supply stability, and cost-effectiveness.
Skyrun Pharma Co., Ld., a core subsidiary of Farmasino Co., Ltd. (“FarmaSino”), participated in the national centralized procurement program for the first time and achieved a notable breakthrough. The company’s Salbutamol Sulfate Injection was successfully selected, representing a significant milestone in FarmaSino’s participation in national-level pharmaceutical procurement programs. This achievement marks Skyrun Pharma’s formal entry into China’s national drug procurement system and reflects its steadily growing competitiveness within the pharmaceutical industry.
This successful bid not only highlights the strong market performance of Skyrun Pharma’s pharmaceutical products but also demonstrates the company’s expanding capabilities in generic drug development, pharmaceutical quality management, and participation in large-scale medical supply programs. It further underscores FarmaSino’s continuous efforts to strengthen its healthcare business portfolio and deepen its presence in both domestic and international pharmaceutical markets.
A Milestone Achievement in National Drug Procurement
The winning product, Salbutamol Sulfate Injection (Approval No.: H20254900), is widely used in clinical practice for the treatment of respiratory diseases associated with bronchospasm. Its key indications include:
Other pulmonary conditions requiring rapid bronchodilation
Salbutamol Sulfate Injection plays an important role in both emergency and routine respiratory care due to its rapid onset of action and well-established clinical efficacy. The successful selection of this product in the national centralized procurement program demonstrates its clinical value, stable product quality, and strong competitiveness under a highly standardized and regulated evaluation system.
For Skyrun Pharma, this selection represents authoritative recognition of its pharmaceutical development and quality assurance capabilities. China’s centralized drug procurement process applies stringent and comprehensive evaluation criteria, including quality consistency, manufacturing compliance, cost-effectiveness, regulatory adherence, and long-term production capacity. Only pharmaceutical enterprises with proven technical strength and reliable supply capabilities can succeed in such a competitive process, making this bid win a meaningful endorsement of Skyrun Pharma’s overall professional standards.
Strengthening R&D and Manufacturing Capabilities Through the MAH System
As the R&D-focused subsidiary of FarmaSino, Skyrun Pharma Co., Ld. holds the Drug Manufacturing Permit under the Marketing Authorization Holder (MAH) system (Category B). This qualification enables the company to independently carry out drug research and development, manage product registration, oversee manufacturing activities, and support commercialization throughout the product lifecycle.
Currently, Skyrun Pharma manages more than 50 active R&D projects and regulatory approvals, covering a diverse range of generic and innovative pharmaceutical products. These projects span multiple therapeutic areas and dosage forms, reflecting the company’s long-term commitment to building a sustainable and competitive product pipeline.
Under the MAH framework, Skyrun Pharma has established an integrated operational system that includes:
Research and Development (R&D)
Regulatory Affairs and registration management
Quality Management and compliance systems
Manufacturing oversight and process supervision
Commercialization and technical support
This full-cycle capability ensures that each pharmaceutical product meets high standards of quality, safety, consistency, and regulatory compliance. The successful inclusion of Salbutamol Sulfate Injection in the national procurement program further validates Skyrun Pharma’s scientific rigor, robust quality management systems, and strong execution capabilities under the MAH model.
Ensuring Stable Supply and Supporting Public Health Development
Winning a bid under China’s national centralized drug procurement program also entails significant responsibility. In addition to offering high-quality pharmaceutical products, selected enterprises are required to ensure stable, continuous, and sufficient supply to healthcare institutions nationwide.
Skyrun Pharma has confirmed that it will fully leverage FarmaSino’s integrated advantages across research, production coordination, and distribution management to fulfill its supply commitments. The company is dedicated to:
Ensuring uninterrupted and scalable manufacturing capacity
Maintaining strict quality control throughout the production process
Strengthening logistics planning and supply chain coordination
Providing consistent and reliable product supply to hospitals and medical institutions
Through these efforts, Skyrun Pharma aims to enhance the availability of essential respiratory medications, support the smooth implementation of national healthcare policies, and contribute positively to public health development. This milestone also marks a new stage in FarmaSino’s strategic growth, positioning the group as a more reliable and trusted participant in China’s pharmaceutical supply system.
About Farmasino Co., Ltd.
Farmasino Co., Ltd. is a subsidiary of Jiangsu Soho Holdings Group, one of China’s Fortune Global 500 enterprises. The company specializes in the international trade of pharmaceutical and healthcare products, supplying clients in over 120 countries and regions worldwide.
As a Vice President Member of the China Chamber of Commerce for Import & Export of Medicines & Health Products, FarmaSino is highly recognized for its:
Excellent customer service
Competitive global presence
Good international reputation
With a diversified product portfolio and a growing network of global partners, the company continues to expand its presence in both domestic and international pharmaceutical markets.
About Skyrun Pharma Co., Ld.
Skyrun Pharma Co., Ld., a wholly owned core subsidiary of FarmaSino, is dedicated to drug development, registration, and technical services. The company maintains close collaborations with major academic and research institutions, including China Pharmaceutical University and Nanjing University of Chinese Medicine, establishing a strong foundation for industry–university–research integration.
Key achievements include:
Obtaining the MAH Drug Manufacturing Permit (Category B) in 2021
Recognition as a National High-Tech Enterprise
CNAS Laboratory Accreditation
Certification under the National Intellectual Property Management System
Establishment of a Jiangsu Provincial Postgraduate Workstation
Multiple prestigious awards, such as:
Jiangsu Top 100 Science & Technology Service Organizations
Nanjing Engineering Technology Research Center for Generic Drug Consistency Evaluation
Nanjing Engineering Research Center
Nanjing Credit Management Demonstration Enterprise
By integrating strong scientific research capacity with high-standard pharmaceutical manufacturing, Skyrun Pharma continues to enhance its competitive edge in the global pharmaceutical industry.
Hot News
EN
